DiaMedica Therapeutics

DMAC (NasdaqCM)

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company working to improve outcomes for people with severe ischemic diseases. Its lead candidate, DM199, is a recombinant human tissue kallikrein-1 in Phase 2/3 for acute ischemic stroke and Phase 2 for preeclampsia, cardio-renal disease, and fetal growth restriction. DM300, recombinant human ulinastatin, is preclinical for inflammatory diseases including acute pancreatitis. Founded in 2000 and based in Minneapolis, Minnesota (formerly DiaMedica Inc.; renamed in Dec 2016).